Chris is a Trader on the Frazier Life Sciences team and focuses on public portfolio company trade execution.
Chris joined the Frazier Life Sciences team as a Trader in April 2021 and focuses on trade execution as part of Frazier’s public portfolio management.
Prior to joining Frazier, Chris was the CEO of a FINRA registered Broker Dealer that garnered one of the first approvals for transacting in digitized private market securities on an SEC Registered Alternative Trading System (“ATS”). Previously, Chris was a trader at Point72 Asset Management where he focused on public Biotechnology companies. Before Point72, Chris was a Director at Leerink Partners (now SVB Leerink), where he spent six years focused on market making in Biotech and Generic Pharmaceuticals companies. Chris began his career in Special Situations Research and transitioned to trading by managing the pre- and post-trade analytics for a program trading desk responsible for transacting on behalf of large pension funds.
Chris earned a Bachelor of Science (Finance) in Business at the University of Colorado at Boulder where he was a member of the Dean’s Cabinet for the Business School.